Category Archives: New Drug Application

Drug pricing: Are we paying for efficacy or innovation?

What if we paid professional athletes only when they won? What if spectators got their tickets refunded whenever the home team lost? That might make that $1,300 Super Bowl ticket a little easier to purchase. And, hey, perhaps that might…

Share

Patient Experience Still Undervalued in Regulating Drugs

As I write this, I’m sitting in the University of British Columbia/Vancouver General Hospital (UBC/VGH) Eye Care Centre, where my husband, Chuck, is completing post-tests at the conclusion of a six-month study on prosopagnosia, otherwise known as face blindness. The…

Share

What Drug Problem?

Pop quiz . . . which market is valued higher, illegal drugs or prescription drugs? Although drug lords and cartels are not apt to file annual reports, the United Nations estimates that 5 percent of the global population now takes…

Share

He Said What?!?! Best Biotech Quotes of 2011

As BioWorld Insight readers know, our “Word on the Street” column provides a sample of the most entertaining and thought-provoking quotes our staff stumbles upon each week. Some are gathered during interviews, some gleaned from analyst reports, and some overheard…

Share

The Good, the Bad and . . . the Huh? A 2011 Biotech Recap

The past year brought the biotech sector a mixed bag of news. Some of it was positive – for instance, the FDA picked up its drug approval pace in 2011 and, in some cases, even surprised the most hardened biotech…

Share

Medical Progress Is Real

SAN FRANCISCO ‑ I’m enough of a geek that I actually enjoy the details, devil and all, and so I love covering scientific conferences. At the same time, they can be daunting. So much scientific progress is incremental. A case…

Share

Truth in Congressional Labeling

S. 990 was signed into law last week. At first glance, it looks like it extends the life of Small Business Administration programs that are near and dear to the bottom line of many small biotechs. But somewhere along its…

Share

Biotech’s Emerging Giant

While attending the China track at this year’s J.P. Morgan conference in January I sat next to a gentleman who was smiling as he scanned the jam-packed penthouse meeting room. Shooting him a questioning glance, he responded with “last year…

Share

Race To Nowhere

Racial profiling – long in the realm of bad law enforcement – was criticized as bad medicine, too, in a recent paper by scientists from the Mount Sinai School of Medicine. The reason? As the authors put it, “cosmopolitan cities…

Share